ARWR
Arrowhead Pharmaceuticals Inc
61.50$
-0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 24.0% | 120.1% | – | – | 21.3% | 209.4% | 1.1% | 22.4% | 2.5% | 2.4% | 8.6% | – | – | |
| 76.0% | -20.1% | – | – | -21.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 598.9% | 3,172.1% | – | – | 557.0% | 5,480.1% | 24.5% | 584.8% | 68.1% | 67.1% | 235.0% | 263.4% | 108.0% | |
| 150.1% | 653.1% | – | – | 109.3% | 1,056.0% | 5.1% | 109.6% | 14.5% | 17.2% | 55.9% | 62.0% | 25.5% | |
| 749.0% | 3,825.2% | – | – | 666.3% | 6,556.5% | 29.8% | 696.2% | 82.8% | 84.5% | 291.6% | 326.0% | 133.8% | |
| -673.0% | -3,845.3% | – | – | -687.6% | -6,456.5% | 70.2% | -596.2% | 17.2% | 15.5% | -191.6% | -226.0% | -33.8% | |
| 32.7% | 151.1% | – | – | 62.1% | 865.8% | 4.0% | 87.8% | 8.5% | 8.5% | 32.3% | 32.6% | 13.8% | |
| -677.1% | -3,905.6% | – | – | -732.5% | -7,004.6% | 68.1% | -645.0% | 14.1% | 10.7% | -186.6% | -237.7% | -37.7% | |
| 12.6% | -93.3% | – | – | 2.3% | 4.1% | 0.3% | -1.6% | 7.8% | 0.0% | 0.0% | 0.0% | 3.0% | |
| -681.4% | -3,741.6% | – | – | -722.9% | -6,923.4% | 68.3% | -631.1% | -9.3% | 11.7% | -180.0% | -258.2% | -47.8% | |
| -620.4% | -3,634.4% | – | – | -649.1% | -5,929.4% | 73.2% | -534.7% | 25.0% | 21.7% | -145.6% | -196.2% | -20.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.